• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Agenus Expands Executive Leadership Team

    7/20/23 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGEN alert in real time by email

    Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer

    Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer

    Stephanie Fagan Appointed Chief Communications Officer

    Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics.

    Chief Commercial Officer, Robin Taylor, Ph.D., is an accomplished leader with demonstrated success in global commercial development in oncology. His expertise in commercialization strategies, market access, and product launches will accelerate Agenus' growth and ultimately enable the delivery of the company's therapies to patients as the company evolves to a multi-product organization.

    Chief Product Strategy and Global Medical Affairs Officer, Homa Yeganegi, brings expertise in medical affairs and a passion for advancing patient care. Her success in building and leading global medical affairs teams will play a pivotal role in deepening physicians' understanding of the transformational potential of botensilimab. By fostering strong relationships with the medical community, she will contribute to the development and future commercialization of the company's immuno-oncology programs.

    Chief Communications Officer, Stephanie Fagan, brings extensive experience working with leading healthcare companies and executing successful communication, investor relations and advocacy strategies. Her proven record in building strong brands and engaging stakeholders will shape Agenus' communication efforts and drive patient-centered initiatives to enhance the potential role of botensilimab in the treatment of cancer.

    "We are at an incredibly exciting juncture in our company's history, with a portfolio of promising therapies showing significant clinical activity across a range of hard-to-treat cancers in patients who have not responded to previous therapies," said Chairman and Chief Executive Officer Garo Armen, Ph.D. "With the addition of Robin, Homa, and Stephanie to our team, Agenus is poised to accelerate our growth and, most importantly, deliver novel therapies that we believe will enhance and extend the lives of patients in need."

    Agenus has a growing body of robust clinical data from trials studying botensilimab in approximately 600 patients. Botensilimab alone, or the botensilimab/balstilimab combination has shown clinical responses across nine metastatic solid tumor cancers. The company is in late-stage development in highly prevalent cancers of the colon, lung, and skin with an estimated market opportunity of 150,000 patients across the United States (U.S.), United Kingdom, France, Spain, Italy, Germany, and Japan1. Agenus plans to submit its first Biologics License Application to the U.S. Food and Drug Administration (FDA) for the approval of the combination in patients with refractory non-MSI-H metastatic colorectal cancer in 2024. The ongoing global randomized phase 2 trial for patients with non-active liver metastases has been granted Fast Track designation from the FDA.

    About Robin Taylor

    Robin Taylor, Ph.D. has extensive experience across oncology global development and commercialization, with a proven track record in building the commercial foundation to execute successful launches. Most recently, Taylor was an independent consultant providing strategic commercial advice to biotechnology companies. Taylor was previously the chief commercial officer at Seagen, where he led the organization through a period of significant growth in preparation for the launches of PADCEV® (enfortumab vedotin), and TUKYSA® (tucatinib). Prior to this role Taylor served as vice president and immuno-oncology franchise head in the oncology business unit at AstraZeneca, where he led the global medicine and product teams responsible for IMFINZI® (durvalumab), and IMJUDO® (tremelimumab). Before joining AstraZeneca, Taylor served in commercial roles of increasing responsibility at Genentech, a member of the Roche Group, contributing to the launch and commercialization of HERCEPTIN® (trastuzumab) and AVASTIN® (bevacizumab), and ultimately serving as vice president, lung and cancer immunotherapy franchise head, global product strategy, responsible for the development and commercialization of ALECENSA® (alectinib) and TECENTRIQ® (atezolizumab) across multiple indications. He received a Doctor of Philosophy in molecular and medical genetics from the University of Toronto; a Master of Business Administration from the University of California, Berkeley; and a Bachelor of Science from the University of British Columbia.

    About Homa Yeganegi

    Homa Yeganegi is an expert leader in building and leading oncology-focused global product strategy and medical affairs, with a strong commitment to medical excellence and patient care. Yeganegi joins Agenus from her position as senior vice president and global program leader at Bristol Myers Squibb (BMS) where she led the global regulatory submission for repotrectinib in non-small cell lung cancer (NSCLC). Prior to BMS, she was senior vice president and head of medical affairs for Turning Point Therapeutics, directing development and commercialization strategies for the U.S. approval of repotrectinib in NSCLC. Prior to that role, Yeganegi was senior vice president and head of global medical and scientific affairs at Halozyme responsible for medical commercialization strategy and operational planning for the company's investigational oncology drug candidate. Yeganegi previously served as vice president of global medical affairs at Clovis Oncology where she directed pre-launch activities for rociletinib in NSCLC in the U.S. and Europe. She also built and led oncology-focused global medical affairs teams at Exelixis, and at Onyx Pharmaceuticals where she led launch planning for carfilzomib in multiple myeloma. She received her Bachelor of Science in biology from the University of Tehran, Iran; her Master of Science in neuroanatomy from the University of Western Australia; and is completing a doctorate in health sciences.

    About Stephanie Fagan

    Stephanie Fagan brings a breadth of expertise across corporate affairs and communications, leading the development and execution of multi-stakeholder communication strategies. She joins Agenus from Pillar Communication, LLC, a consulting firm providing fractional chief communications officer leadership. Prior to that, she was senior vice president and chief communications officer at Acadia Pharmaceuticals, overseeing all internal and external communications. Fagan joined Acadia from bluebird bio, Inc., where she was senior vice president, corporate communications, and built the first communications function as the company transitioned from a clinical-stage to commercial-stage company. Prior to bluebird, Fagan led the corporate affairs functions at Alexion, Shire and West Health and has experience overseeing corporate, financial, product and internal communications as well as corporate social responsibility, patient advocacy, and government affairs. Over the course of her career, Fagan has served in positions of increasing influence and impact in the healthcare industry, including roles at Johnson & Johnson, Allergan, Pharmacia, Inc. (now Pfizer), and Boston Scientific Corporation. Fagan earned a Master of Science in communications from Boston University and a Bachelor of Arts in English from Wheaton College.

    About Botensilimab

    Botensilimab, an investigational multifunctional CTLA-4 antibody, is designed to extend immunotherapy benefits to "cold" tumors, which have not historically responded to standard of care or other investigational therapies. Besides binding to the CTLA-4 receptor, its Fc-enhanced structure induces a memory immune response, downregulates regulatory T cells, and activates T cells, thereby enhancing immune responses. Approximately 600 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT05608044, NCT05630183, and NCT05529316.

    About Agenus

    Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company's mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.

    Forward-Looking Statements

    This press release contains forward-looking statements under the safe harbor provisions of federal securities laws. These include statements related to botensilimab's and balstilimab's regulatory strategy and use, such as anticipated therapeutic benefit, efficacy, mechanism of action, potency, durability, and safety profile of the company's therapeutic candidates. Any statements containing "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," "establish," "potential," "superiority," "best in class," and similar expressions signify forward-looking statements. Actual results could differ materially due to risks and uncertainties, including those described under the Risk Factors section in our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus urges investors not to place significant reliance on the forward-looking statements in this release. These statements only reflect the views as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

    1 Data/information supplied by Kantar Health, LLC.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230720314820/en/

    Get the next $AGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGEN

    DatePrice TargetRatingAnalyst
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    7/18/2024Outperform → Mkt Perform
    William Blair
    7/18/2024$9.00Buy → Neutral
    H.C. Wainwright
    6/6/2023$8.00Outperform
    Robert W. Baird
    6/6/2023$60.00 → $80.00Outperform
    Robert W. Baird
    2/28/2023$8.00Buy
    H.C. Wainwright
    9/28/2022$5.00Outperform
    SMBC Nikko
    3/2/2022$12.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu

      4/29/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

      Initial results from NEOASIS demonstrate BOT/BAL efficacy in the neoadjuvant setting across multiple MSS and MSI-H solid tumors Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficient (dMMR/MSI-H) solid tumors. These findings include the first reported outcomes with BOT/BAL outside colo

      4/28/25 3:30:00 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

      Durable responses observed in heavily pretreated HCC patients who progressed on approved immunotherapies Agenus Inc. (NASDAQ:AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The HCC cohort comprised patients with difficult-to-treat disease who had progressed following standard treatments, including approved immunotherapies. "The treatment of patients with advanced HCC who progressed on immune

      4/25/25 1:05:00 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agenus downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

      7/19/24 7:27:15 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by William Blair

      William Blair downgraded Agenus from Outperform to Mkt Perform

      7/18/24 1:59:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00

      7/18/24 12:35:32 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Financials

    Live finance-specific insights

    See more

    $AGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu

      4/29/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

      Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati

      3/11/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/886193189.

      2/25/25 8:26:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 7:58:18 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 9:21:26 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      6/10/24 12:15:17 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Agenus Announces Appointment of Tom Harrison to Board of Directors

      Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

      8/8/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

      Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

      6/17/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Expands Executive Leadership Team

      Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

      7/20/23 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Buell Jennifer was granted 581 shares, increasing direct ownership by 3% to 19,738 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/6/25 5:21:12 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Armen Garo H was granted 5,260 shares, increasing direct ownership by 3% to 181,060 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/5/25 4:05:04 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Buell Jennifer was granted 869 shares, increasing direct ownership by 5% to 19,157 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/5/25 4:05:05 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Agenus Inc.

      DEFR14A - AGENUS INC (0001098972) (Filer)

      5/5/25 4:15:11 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Agenus Inc.

      DEF 14A - AGENUS INC (0001098972) (Filer)

      4/30/25 4:05:22 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Agenus Inc.

      PRE 14A - AGENUS INC (0001098972) (Filer)

      4/18/25 4:30:17 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      2/15/24 6:59:48 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      11/17/23 4:22:11 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care